Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523707 | 0.75 | TOP1 (0.41) | CNR2 | |
| SCHEMBL6513337 | 0.73 | PIK3R1 (0.45) | CASP3CNR2ALDH1A1DYRK1ACDK1 | |
| SCHEMBL6508889 | 0.72 | ATR (0.42) | CNR2DYRK1A | |
| SCHEMBL18281904 | 0.71 | GAA (0.41) | CNR2ALDH1A1HPGDCYP2C19MAPK8 | |
| SCHEMBL6523125 | 0.71 | PTGS2 (0.38) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6509129 | 0.70 | HPGD (0.33) | CASP3CNR2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6510884 | 0.69 | CHEK1 (0.56) | CASP3CNR2ALDH1A1DYRK1ACDK1 | |
| SCHEMBL6502931 | 0.69 | ELANE (0.51) | CNR2ALDH1A1HPGDCDK1MAPK8 | |
| SCHEMBL29593200 | 0.69 | ELANE (0.51) | CNR2ALDH1A1HPGDCDK1MAPK8 | |
| SCHEMBL23219108 | 0.69 | RXRA (0.39) | CNR2ALDH1A1CDK1MAPK8RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CASP3 3036/4885CNR2 3139/4885ALDH1A1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.